• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过细胞外囊泡靶向激活的JAK-STAT通路克服铂耐药性卵巢癌

Overcoming platinum-resistant ovarian cancer targeting the activated JAK-STAT pathways via extracellular vesicles.

作者信息

Suzuki Kazuhiro, Yokoi Akira, Yoshida Kosuke, Suzuki Hironori, Kitagawa Masami, Asano-Inami Eri, Matsuo Seiko, Yoshihara Masato, Tamauchi Satoshi, Yoshikawa Nobuhisa, Niimi Kaoru, Sudo Tamotsu, Yamaguchi Satoshi, Yamamoto Yusuke, Kajiyama Hiroaki

机构信息

Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

Institute for Advanced Research, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan.

出版信息

Commun Biol. 2025 Aug 29;8(1):1305. doi: 10.1038/s42003-025-08771-9.

DOI:10.1038/s42003-025-08771-9
PMID:40883550
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12397317/
Abstract

Platinum-resistant ovarian cancer (PROC) is a clinically severe unresolved issue, and it remains unclearly defined by molecular biology. Extracellular vesicles (EVs) play an essential role in cell-to-cell communication in the tumor microenvironment. This study aimed to investigate the molecular mechanisms of PROC, focusing on the unique ascites environment of ovarian cancer. Multi-transcriptome analyses using clinical samples revealed that PROC exhibited an activated Janus kinase (JAK)/signal transducer and activator of transcription pathway with high JAK1 expression in cancer cells. Immunohistochemistry for patient tissues confirmed the negative association between JAK1 expression and platinum response. JAK inhibitors were effective in PROC cell lines and cell- and patient-derived xenograft models, as well as synergistic with platinum. Furthermore, small RNA sequencing indicated that activated peritoneal mesothelial cell-derived EVs enriched in miR135a-5p increased JAK expression and platinum resistance in cancer cells. Collectively, EVs in ascites regulated platinum sensitivity in ovarian cancer cells, and JAK targeting therapeutic strategy overcomes PROC.

摘要

铂耐药卵巢癌(PROC)是一个临床上严重且尚未解决的问题,其分子生物学定义仍不明确。细胞外囊泡(EVs)在肿瘤微环境中的细胞间通讯中起着至关重要的作用。本研究旨在探讨PROC的分子机制,重点关注卵巢癌独特的腹水环境。使用临床样本进行的多转录组分析显示,PROC在癌细胞中表现出激活的Janus激酶(JAK)/信号转导和转录激活因子通路,JAK1表达较高。对患者组织进行的免疫组织化学证实了JAK1表达与铂反应之间的负相关。JAK抑制剂在PROC细胞系、细胞和患者来源的异种移植模型中有效,并且与铂具有协同作用。此外,小RNA测序表明,富含miR135a - 5p的激活腹膜间皮细胞衍生的EVs增加了癌细胞中的JAK表达和铂耐药性。总体而言,腹水中的EVs调节卵巢癌细胞的铂敏感性,靶向JAK的治疗策略可克服PROC。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/c50c306a5bd0/42003_2025_8771_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/7af378fc4695/42003_2025_8771_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/0b281ae17796/42003_2025_8771_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/7d8f808bd3eb/42003_2025_8771_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/48d11b60f26d/42003_2025_8771_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/faea37718269/42003_2025_8771_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/c50c306a5bd0/42003_2025_8771_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/7af378fc4695/42003_2025_8771_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/0b281ae17796/42003_2025_8771_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/7d8f808bd3eb/42003_2025_8771_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/48d11b60f26d/42003_2025_8771_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/faea37718269/42003_2025_8771_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9bec/12397317/c50c306a5bd0/42003_2025_8771_Fig6_HTML.jpg

相似文献

1
Overcoming platinum-resistant ovarian cancer targeting the activated JAK-STAT pathways via extracellular vesicles.通过细胞外囊泡靶向激活的JAK-STAT通路克服铂耐药性卵巢癌
Commun Biol. 2025 Aug 29;8(1):1305. doi: 10.1038/s42003-025-08771-9.
2
FCGBP promotes ovarian cancer progression via activation of IL-6/JAK-STAT signaling pathway.FCGBP通过激活IL-6/JAK-STAT信号通路促进卵巢癌进展。
J Transl Med. 2025 Jul 25;23(1):827. doi: 10.1186/s12967-025-06854-z.
3
piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer.piR-1919609 是逆转卵巢癌铂耐药的理想潜在靶点。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241249692. doi: 10.1177/15330338241249692.
4
Resveratrol Contrasts LPA-Induced Ovarian Cancer Cell Migration and Platinum Resistance by Rescuing Hedgehog-Mediated Autophagy.白藜芦醇通过挽救 Hedgehog 介导的自噬来对抗 LPA 诱导的卵巢癌细胞迁移和铂耐药性。
Cells. 2021 Nov 17;10(11):3213. doi: 10.3390/cells10113213.
5
Janus kinase/signal transducer and activator of transcription signalling pathway is involved in the immune mechanism of bullous pemphigoid.Janus激酶/信号转导子和转录激活子信号通路参与大疱性类天疱疮的免疫机制。
Br J Dermatol. 2025 Aug 18;193(3):521-531. doi: 10.1093/bjd/ljaf219.
6
EPHX1 enhances drug resistance to regorafenib by activating the JAK/STAT signaling pathway in hepatocellular carcinoma cell lines.EPHX1通过激活肝癌细胞系中的JAK/STAT信号通路增强对瑞戈非尼的耐药性。
Hereditas. 2025 Jul 31;162(1):148. doi: 10.1186/s41065-025-00517-1.
7
Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer.卵巢癌中的细胞内在铂反应及相关遗传和基因表达特征
Cancer Gene Ther. 2025 Jul 19. doi: 10.1038/s41417-025-00941-5.
8
STC1 promotes paclitaxel resistance in oral squamous cell carcinoma by inhibiting oxidative stress via activating the JAK/STAT signaling pathway.STC1通过激活JAK/STAT信号通路抑制氧化应激,从而促进口腔鳞状细胞癌对紫杉醇的耐药性。
Life Sci. 2025 Sep 15;377:123787. doi: 10.1016/j.lfs.2025.123787. Epub 2025 Jun 3.
9
Tumor Small Extracellular Vesicle-Transmitted LncRNA CATED Promotes Platinum-Resistance in High-Grade Serous Ovarian Cancer.肿瘤小细胞外囊泡传递的长链非编码RNA CATED促进高级别浆液性卵巢癌的铂耐药性。
Adv Sci (Weinh). 2025 Aug;12(31):e05963. doi: 10.1002/advs.202505963. Epub 2025 Jun 10.
10
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.厄洛替尼或吉非替尼治疗铂类预处理复发的非小细胞肺癌和卵巢癌:系统评价。
Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24.

本文引用的文献

1
Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.Ruxolitinib 联合一线新辅助治疗晚期卵巢癌的 I 期和随机 II 期研究:NRG 肿瘤学组研究。
J Clin Oncol. 2024 Jul 20;42(21):2537-2545. doi: 10.1200/JCO.23.02076. Epub 2024 May 22.
2
Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment.具有间充质特征的间皮细胞通过形成促肿瘤微环境增强腹膜扩散。
Cell Rep. 2024 Jan 23;43(1):113613. doi: 10.1016/j.celrep.2023.113613. Epub 2024 Jan 16.
3
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
化疗耐药性高级别浆液性卵巢癌的蛋白质基因组分析。
Cell. 2023 Aug 3;186(16):3476-3498.e35. doi: 10.1016/j.cell.2023.07.004.
4
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer.单细胞分析表明腹水在重塑卵巢癌原发和转移瘤生态系统中起作用。
Nat Cancer. 2023 Aug;4(8):1138-1156. doi: 10.1038/s43018-023-00599-8. Epub 2023 Jul 24.
5
Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer.化疗诱导携带 ADAM17 的 EV 释放作为卵巢癌潜在耐药机制。
J Extracell Vesicles. 2023 Jul;12(7):e12338. doi: 10.1002/jev2.12338.
6
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
7
Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance.异位 JAK-STAT 激活使细胞向干细胞样和多能性状态转变,从而赋予对 AR 靶向治疗的抗性。
Nat Cancer. 2022 Sep;3(9):1071-1087. doi: 10.1038/s43018-022-00431-9. Epub 2022 Sep 5.
8
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling.前列腺癌中的谱系可塑性取决于 JAK/STAT 炎症信号通路。
Science. 2022 Sep 9;377(6611):1180-1191. doi: 10.1126/science.abn0478. Epub 2022 Aug 18.
9
Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment.卵巢癌腹水微环境中生长因子代谢关系的新观点。
Semin Cancer Biol. 2022 Nov;86(Pt 2):709-719. doi: 10.1016/j.semcancer.2022.03.004. Epub 2022 Mar 5.
10
The systemic treatment of recurrent ovarian cancer revisited.复发性卵巢癌的系统治疗再探。
Ann Oncol. 2021 Jun;32(6):710-725. doi: 10.1016/j.annonc.2021.02.015. Epub 2021 Mar 3.